There are currently 1249 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
Recruiting
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolera... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
Register for Updates
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
NCT04839991
Recruiting
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary RP2D.In addition this study will assess the safety and efficacy of CB307 when given in combination with pembrolizumab (KEYTRUDA®) in patients with metastatic PSMA+ castration-resistant cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of Washington, Seattle, Washington
Conditions: Advanced and/or Metastatic Solid Tumours
Register for Updates
Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users
NCT05306561
Recruiting
To evaluate dry eye symptoms and contact lens wearing times after a single iLux treatment by evaluating change from baseline in OSDI scores, subjective CLDEQ8 and CL wearing time questionnaires, and meibomian gland secretion scores.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Periman Eye Institute, Seattle, Washington
Conditions: Meibomian Gland Dysfunction, Dry Eye
Register for Updates
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04964518
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2023
Locations: Swedish Medical Center, Seattle, Washington
Conditions: AML, Adult
Register for Updates
Desara ® One Single Incision Sling 522 Study
NCT04772131
Recruiting
A post-market study to compare the safety and effectiveness of the Desara® One Single Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a period of 36 months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2023
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Stress Urinary Incontinence
Register for Updates
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
NCT03420014
Recruiting
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
Gender:
ALL
Ages:
Between 16 years and 100 years
Trial Updated:
10/06/2023
Locations: Seattle Cancer Care Alliance 825 Eastlake Ave. E. Seattle, WA 98109 Mail Stop CE2-128, Seattle, Washington
Conditions: Leiomyosarcoma
Register for Updates
The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies
NCT06072976
Recruiting
This study explores the use of an exclusive human milk diet versus standard feeding practices to compare the influence on feeding outcomes and the gut bacteria in infants with intestinal differences.
Gender:
ALL
Ages:
Between 0 days and 55 years
Trial Updated:
10/03/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Gastrointestinal Complication, Intestinal Obstruction, Gastroschisis, Hirschsprung Disease, Omphalocele, Midgut Volvulus
Register for Updates
Comparison Neuromuscular Blockade Monitors
NCT05006807
Recruiting
The overall objective of this research is to evaluate different laboratory-built and commercially available sensors used to measure the effects of neuromuscular blocking drugs on neuromuscular function during surgery, by measuring evoked thumb twitch response to ulnar nerve stimulation (also known as "twitch monitoring"). The specific aim is to compare mechanomyography, which is the "gold standard" laboratory measurement to assess neuromuscular blockade, to the sensors used in commercially avail... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/18/2023
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Neuromuscular Blockade
Register for Updates
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
NCT04131036
Recruiting
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compar... Read More
Gender:
MALE
Ages:
16 years and above
Trial Updated:
08/31/2023
Locations: Washington Center for Bleeding Disorders at Washington Institute for Coagulation, Seattle, Washington
Conditions: Hemophilia A
Register for Updates
Reach Out and Read (ROR) in the Neonatal Intensive Care Unit (NICU) Study
NCT06002360
Recruiting
The goal of this clinical trial is to learn about the effects of the Reach Out and Read program on infants and their families in the neonatal ICU. The main goals of this study are: * To complete a needs assessment for literacy interventions in the NICU population through evaluating baseline home literacy scores. * To evaluate the effects of the ROR intervention on parental stress levels as assessed by the 6-question State-Trait Anxiety Index (STAI-6) * To evaluate the effects of the ROR interve... Read More
Gender:
ALL
Ages:
14 days and below
Trial Updated:
08/15/2023
Locations: University of Washington Medical Center NICU, Seattle, Washington
Conditions: Anxiety, Parent-Child Relations, Literacy
Register for Updates
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115
Recruiting
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Register for Updates
Venetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Recruiting
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Register for Updates